Clinical trial

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

NCT00001042

Drugs and interventions used in this trial

8 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention Aluminum hydroxide Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Lipid A, Monophosphoryl Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Lipid A, Liposome-encapsulated monophosphoryl Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Syntex adjuvant formulation Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention MF59 Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Threonyl Muramyl Dipeptide Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention rgp120/HIV-1 SF-2 Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention MTP-PE/MF59 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start dateUnknown

PhasePHASE1

Conditions

HIV Infectionsunresolved

Interventions

Aluminum hydroxideBIOLOGICAL

Lipid A, MonophosphorylBIOLOGICAL

Lipid A, Liposome-encapsulated monophosphorylBIOLOGICAL

Syntex adjuvant formulationBIOLOGICAL

MF59BIOLOGICAL

Threonyl Muramyl DipeptideBIOLOGICAL

rgp120/HIV-1 SF-2BIOLOGICAL

MTP-PE/MF59BIOLOGICAL

Sponsors & collaborators

National Institute of Allergy and Infectious Diseases (NIAID)lead sponsor

Mapped research locations

St LouisMissouri, United States1 SeattleWashington, United States1 RochesterNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00001042 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.